These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11554765)

  • 1. Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain.
    Ariumi Y; Kaida A; Hatanaka M; Shimotohno K
    Biochem Biophys Res Commun; 2001 Sep; 287(2):556-61. PubMed ID: 11554765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity.
    Zauli G; La Placa M; Vignoli M; Re MC; Gibellini D; Furlini G; Milani D; Marchisio M; Mazzoni M; Capitani S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):306-16. PubMed ID: 7552492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator.
    Roof P; Ricci M; Genin P; Montano MA; Essex M; Wainberg MA; Gatignol A; Hiscott J
    Virology; 2002 Apr; 296(1):77-83. PubMed ID: 12036319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of the N-terminal domain of Tat protein of the human immunodeficiency virus type 1.
    Reddy MV; Desai M; Jeyapaul J; Prasad DD; Seshamma T; Palmeri D; Khan SA
    Oncogene; 1992 Sep; 7(9):1743-8. PubMed ID: 1501886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
    Gabizon R; Mor M; Rosenberg MM; Britan L; Hayouka Z; Kotler M; Shalev DE; Friedler A
    Biopolymers; 2008; 90(2):105-16. PubMed ID: 18189286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.
    Desfosses Y; Solis M; Sun Q; Grandvaux N; Van Lint C; Burny A; Gatignol A; Wainberg MA; Lin R; Hiscott J
    J Virol; 2005 Jul; 79(14):9180-91. PubMed ID: 15994812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication.
    Verhoef K; Koper M; Berkhout B
    Virology; 1997 Oct; 237(2):228-36. PubMed ID: 9356335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen-mediated protection against HIV Tat protein-induced inflammatory pathways in human vascular endothelial cells.
    Lee YW; Eum SY; Nath A; Toborek M
    Cardiovasc Res; 2004 Jul; 63(1):139-48. PubMed ID: 15194470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of HIV-1 virus replication using small soluble Tat peptides.
    Agbottah E; Zhang N; Dadgar S; Pumfery A; Wade JD; Zeng C; Kashanchi F
    Virology; 2006 Feb; 345(2):373-89. PubMed ID: 16289656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the human immunodeficiency virus type I long terminal repeat by 1 alpha,25-dihydroxyvitamin D3.
    Nevado J; Tenbaum SP; Castillo AI; Sánchez-Pacheco A; Aranda A
    J Mol Endocrinol; 2007 Jun; 38(6):587-601. PubMed ID: 17556530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel approach to protein-protein interaction: complex formation between the p53 tumor suppressor and the HIV Tat proteins.
    Longo F; Marchetti MA; Castagnoli L; Battaglia PA; Gigliani F
    Biochem Biophys Res Commun; 1995 Jan; 206(1):326-34. PubMed ID: 7818536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides.
    Devadas K; Boykins RA; Hardegen NJ; Philp D; Kleinman HK; Osa EO; Wang J; Clouse KA; Wahl LM; Hewlett IK; Rappaport J; Yamada KM; Dhawan S
    Peptides; 2006 Apr; 27(4):611-21. PubMed ID: 16256245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A protein phosphatase from human T cells augments tat transactivation of the human immunodeficiency virus type 1 long-terminal repeat.
    Bharucha DC; Zhou M; Nekhai S; Brady JN; Shukla RR; Kumar A
    Virology; 2002 Apr; 296(1):6-16. PubMed ID: 12036313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis.
    Boykins RA; Mahieux R; Shankavaram UT; Gho YS; Lee SF; Hewlett IK; Wahl LM; Kleinman HK; Brady JN; Yamada KM; Dhawan S
    J Immunol; 1999 Jul; 163(1):15-20. PubMed ID: 10384093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus-1 Tat protein up-regulates interleukin-6 and interleukin-8 expression in human breast cancer cells.
    Lee YW; Hirani AA; Kyprianou N; Toborek M
    Inflamm Res; 2005 Sep; 54(9):380-9. PubMed ID: 16273337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication.
    Accolla RS; Mazza S; De Lerma Barbaro A; De Maria A; Tosi G
    Eur J Immunol; 2002 Oct; 32(10):2783-91. PubMed ID: 12355430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-16 represses HIV-1 promoter activity.
    Maciaszek JW; Parada NA; Cruikshank WW; Center DM; Kornfeld H; Viglianti GA
    J Immunol; 1997 Jan; 158(1):5-8. PubMed ID: 8977168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H. saimiri tyrosine-kinase interacting protein inhibits Tat function: a prototypic strategy for restricting HIV-1-induced cytopathic effects in immune cells.
    Raymond AD; Hasham M; Tsygankov AY; Henderson EE
    Virology; 2006 Sep; 352(2):253-67. PubMed ID: 16780912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 gene expression and replication in neuronal and glial cell lines with immature phenotype: effects of nerve growth factor.
    Ensoli F; Ensoli B; Thiele CJ
    Virology; 1994 May; 200(2):668-76. PubMed ID: 8178451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein.
    Grégoire C; Péloponèse JM; Esquieu D; Opi S; Campbell G; Solomiac M; Lebrun E; Lebreton J; Loret EP
    Biopolymers; 2001; 62(6):324-35. PubMed ID: 11857271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.